F-1/A: Phaos Technology Holdings Files for NYSE American IPO Amidst Significant Revenue Decline and Going Concern Doubts

Phaos Technology Holdings (Cayman) Limited, a microscopy solutions provider, has filed for an initial public offering on the NYSE American, seeking to raise approximately $11.24 million, despite reporting an 82.7% revenue decrease and a 31.5% increase in net loss for the six months ended October 31, 2024, raising substantial doubt about its ability to continue as a going concern.

Summary

• Phaos Technology Holdings (Cayman) Limited is an investment holding company that assembles and commercializes advanced microscopy-related solutions, technologies, and products, including super-resolution imagers, specialized microscopes, and 3D real-time image magnifiers.
• The company utilizes patented microsphere-assisted technology to achieve imaging down to 137nm, significantly beyond the 200nm optical limit of traditional microscopes, and provides complimentary proprietary software with Artificial Intelligence (AI) components for research, quality assurance/control (QA/QC), and diagnostics.
• For the six months ended October 31, 2024, revenue decreased by 82.7% to S$63,129 (US$47,720) from S$365,415 (US$276,217) in the prior comparable period, primarily due to a reduction in sales orders from its largest customers.
• Net loss for the six months ended October 31, 2024, increased by 31.5% to S$2,019,092 (US$1,526,234) from S$1,535,175 (US$1,160,438) in the prior comparable period, driven by decreased revenue and increased employee benefits and other operating expenses.
• The accumulated deficit as of October 31, 2024, was S$9,049,158 (US$6,840,259), an increase of 45.8% from October 31, 2023.
• The company reported a negative cash flow from operations of S$1,928,899 (US$1,458,055) for the six months ended October 31, 2024, against a cash balance of S$231,655 (US$175,108), which raises substantial doubt about its ability to continue as a going concern.
• The company plans to raise approximately US$11.24 million in net proceeds from the IPO, with 15% allocated to product R&D, 20% to supply chain expansion, 5% to marketing, and 60% to general working capital and corporate purposes.
• Phaos Technology Holdings operates with a dual-class share structure, where Class A Ordinary Shares have one vote and Class B Ordinary Shares have twenty votes, resulting in concentrated control by the principal shareholder, Beh Hook Seng, who will hold approximately 62.4% of the total voting power post-IPO.
• The company has identified material weaknesses in its internal controls over financial reporting, including a lack of sufficient skilled staff with U.S. GAAP and SEC reporting knowledge, and a lack of formal accounting policies and procedures manual.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to severe revenue decline, increased losses, explicit 'going concern' doubt, and significant customer concentration. While the company highlights innovative technology and growth strategies, the immediate financial performance and liquidity issues overshadow these positives, indicating a high-risk investment.

Positives

• The company possesses patented microsphere-assisted technology that significantly increases magnification of optical microscopes, allowing imaging down to 137nm, which is considered super-resolution in the optical industry.
• Proprietary in-house software with Artificial Intelligence (AI) components is provided complimentary with hardware, enabling advanced functionalities like recognition patterns for research, QA/QC, and diagnostics.
• The company offers turn-key solutions tailored to customer needs, integrating hardware with customized computer vision implementations.
• A strong emphasis is placed on reliable after-sales support, with a dedicated team of experts and software development personnel.
• The company has an experienced management team, including CEO Andrew Yeo with over two decades in technology and COO Tay Beng Boon with over 25 years in engineering.
• Strategic growth plans include expanding into new countries in Southeast Asia, the Middle East, the United States, and Europe through joint ventures, strategic alliances, and increased marketing efforts.
• Ongoing research and development activities are focused on improving working distance of microsphere lenses, 3D analysis solutions, fully automated zoom microscopy, digital pathology for cancer cell analysis with AI, and enhanced AI/cloud computing capabilities.
• The company has secured ISO 9001/14001/45001 certifications, demonstrating commitment to quality, environmental management, and occupational health and safety.
• Phaos Technology Holdings has received several prestigious awards, including the Titan Business Award for Most Innovative Company of the Year 2023 and the Stevie Award for Innovation in Technology Development in 2023.

Negatives

• Revenue for the six months ended October 31, 2024, significantly decreased by 82.7% to S$63,129 (US$47,720) from S$365,415 (US$276,217) in the prior comparable period.
• Net loss for the six months ended October 31, 2024, increased by 31.5% to S$2,019,092 (US$1,526,234), and the accumulated deficit grew by 45.8% to S$9,049,158 (US$6,840,259).
• The company has incurred operating losses and negative cash flow since inception, with a negative cash flow from operations of S$1,928,899 (US$1,458,055) for the six months ended October 31, 2024, raising substantial doubt about its ability to continue as a going concern.
• Customer concentration is very high, with the top 5 customers accounting for 99.9% of total revenue for the six months ended October 31, 2024, and the largest customer alone accounting for 60%.
• The company has provided a significant loan of S$1,582,604 (US$1,196,290) to PT Neura Integrasi Solusi, an Indonesian startup with limited operating history and revenue, posing a risk of non-recovery.
• Material weaknesses in internal control over financial reporting have been identified, including a lack of sufficient skilled staff with U.S. GAAP and SEC reporting knowledge, and a lack of formal accounting policies and procedures manual.
• The dual-class share structure with Class B shares having 20 votes per share concentrates voting power with the controlling shareholder, potentially limiting the influence of other shareholders.
• The company does not intend to pay dividends in the foreseeable future, meaning investors must rely solely on share price appreciation for returns.

Risks

• The company is an early revenue stage company and has incurred operating losses since inception, with no certainty of attaining profitability.
• Substantial doubt exists about the company's ability to continue as a going concern due to ongoing net losses and negative cash flow from operations, requiring additional capital raises.
• Fluctuations in prices and quantities of materials and components used in manufacturing microscopy equipment could negatively impact profitability.
• High customer concentration exposes the company to significant risk if major customers change business strategies, downsize, or fail to make timely payments.
• The company's continued success is highly dependent on key management personnel, particularly CEO Andrew Yeo, and the loss of such individuals could severely disrupt the business.
• Geographic risk exists as substantially all revenue is derived from Asia, making the company susceptible to economic or political disruptions in those regions.
• Major failures or malfunctions in microscopy equipment could adversely affect reputation and profitability, especially if not covered by insurance.
• A significant failure or deterioration in quality control systems could have a material adverse effect on business and operating results.
• The company may be affected by breaches of lease agreements, potentially incurring significant remediation costs.
• Increased competition in the microscopy equipment business may affect the company's ability to maintain market share and growth.
• Supply chain interruptions, including those from third-party logistics providers and geopolitical conflicts, could affect revenue and profitability.
• The company is exposed to risks arising from fluctuations in foreign currency exchange rates, impacting the value of proceeds and dividends.
• Inability to obtain necessary approvals or certifications for microscopy equipment in various jurisdictions could harm the business.
• Negative publicity could damage the company's reputation and hinder customer acquisition and retention.
• Failure to maintain and protect intellectual property, or assertions of infringement by third parties, could harm the business.
• Risks related to product recalls could significantly impact operations and financial condition.
• The loan to PT Neura Integrasi Solusi carries significant risk due to PT Neura's early development stage, limited operating history, and financial challenges, with no assurance of full recovery.
• An active trading market for Class A Ordinary Shares may not be established or maintained, leading to significant price fluctuations and potential losses for investors.
• The company may not maintain its listing on NYSE American, which could limit investor's ability to trade shares and subject the company to additional restrictions.
• The trading price of Class A Ordinary Shares may be volatile and experience extreme run-ups or rapid declines, unrelated to actual operating performance.
• Failure to implement and maintain an effective system of internal controls over financial reporting could lead to inaccuracies and affect investor confidence.
• New investors will experience immediate and substantial dilution due to the public offering price being significantly higher than the net tangible book value per share.
• The controlling shareholder's substantial influence over the company may not align with other shareholders' interests and could prevent certain transactions.
• As a controlled company and foreign private issuer, the company may rely on exemptions from certain corporate governance requirements, potentially affording less protection to shareholders.
• Judgments obtained against the company or its auditor by shareholders may not be enforceable in the Cayman Islands or Singapore.
• The company may be classified as a passive foreign investment company (PFIC), leading to adverse U.S. federal income tax consequences for U.S. taxpayers.
• The company will incur significantly increased costs and management time as a public reporting company.
• Future grants of employee share options and other share-based awards may result in significant compensation expenses and dilute ownership interests.

Future Outlook

The company expects to diversify its customer base to increase and stabilize product sales, reducing concentration on top customers. Service revenue is anticipated to contribute a greater percentage of total revenue as the product and software range expands. The company plans to continue investing in product development, expanding its supply chain, and increasing marketing efforts, particularly shifting to digital marketing in Southeast Asia, China, Taiwan, and Korea, and expanding physical presence to the Middle East, the United States, and Europe. Future product development includes improving microsphere lens working distance, 3D analysis solutions, fully automated zoom microscopy, digital pathology solutions for cancer cell analysis with AI, and enhanced AI/cloud computing capabilities. Calibration and certification services are expected to be offered by Q2 2025 to generate recurring income.

Management Comments

• We believe that this is considered by the optical industry as a super resolution optical microscopy solution.
• We believe in our strong corporate culture which emphasizes the creation of shareholder value.
• We expect that the diversification of our customer base will allow us to increase and stabilize our product sales through a larger customer base and lower concentration of top customers which we are working actively to broaden.
• As we grow our product and software range, we expect that service revenue will continue to contribute a greater percentage of our revenue going forward.
• We believe that we are well positioned to compete in the industry because of our strong and stable relationships with our suppliers and customers, our experienced management team, our integrated software solutions within our product portfolio, our innovative and turn-key solutions, our adaptive business model, and our reliable after-sales support.
• We are confident that increased market penetration [through PT Neura] will result in exponential revenue generation, which will further assist PT Neura's ability to pay back the loan.

Industry Context

Phaos Technology Holdings operates in the growing and increasingly competitive microscopy equipment industry. Its patented microsphere-assisted technology offers a unique selling proposition by enabling super-resolution imaging beyond traditional optical limits, positioning it as an innovator. The integration of proprietary AI software into its hardware aligns with broader industry trends towards smart, automated, and data-driven solutions in scientific research, manufacturing, and healthcare. The company's focus on turn-key solutions and after-sales support aims to differentiate it in a market with established competitors like Keyence Corp., Nikon Corp., Olympus Corp., and Hirox Co. Ltd. Its expansion strategy into Southeast Asia, the Middle East, US, and Europe reflects the global nature of the microscopy market and the pursuit of new growth opportunities beyond its primary markets of Singapore and Vietnam. The collaboration with PT Neura Integrasi Solusi for biomedical scanning software also indicates a strategic move into the digital pathology and healthcare technology sector, leveraging AI and cloud computing trends.

Comparison to Industry Standards

• Phaos Technology's super-resolution imagers can achieve imaging down to 137nm, which is superior to traditional optical microscopes that typically see up to 250nm (or 220nm as stated in one section), allowing clients to see beyond the optical limit.
• The company claims to be the only commercially available advanced optical microscope that can see below the 200nm optical limit within a commercially viable working distance, differentiating it from competitors like Keyence Corp. (IM Series, VHX Series), Nikon Corp. (LV Series, ECLIPSE Series), Olympus Corp. (MX Series, DSX Series, CX Series), and Hirox Co. Ltd (HRX Series).
• The gross margin range of 20% to 40% for its product ranges is stated as competitive, but no direct comparison to industry averages or specific competitors' margins is provided.
• The average accounts receivable turnover days of 208 days for the six months ended October 31, 2024, is significantly higher than the 80 days for the year ended April 30, 2024, and the typical 30-day credit terms, suggesting a deterioration in collection efficiency compared to its own historical performance and standard industry practices.
• The company's reliance on a few top customers (99.9% of revenue from top 5 for 6 months ended Oct 31, 2024) indicates a higher concentration risk compared to a diversified customer base typically seen in mature industry players.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any significant legal proceedings in Singapore or outside of Singapore as of the date of the prospectus.

Related Party Transactions

• The company has received advances from its major shareholder, TongHuai SG Enterprise Pte. Ltd., for business working purposes.
• The payable balance due to TongHuai SG Enterprise Pte. Ltd. was S$1,145,423 (US$865,825) as of October 31, 2024.
• These advances are interest-free, unsecured, and due on demand without a formal agreement.
• On February 15, 2025, the company obtained a shareholder loan from TongHuai SG Enterprise Pte. Ltd. of S$1 million with an additional option of S$1 million.

Stakeholder Impact

• **Shareholders**: Face significant dilution from the IPO, high risk due to going concern doubts, and limited influence on corporate matters due to the dual-class share structure and controlled company status. Returns are solely dependent on share price appreciation as no dividends are planned.
• **Employees**: The company plans to hire additional personnel and adopt an employee share incentive plan, potentially benefiting employees through share-based compensation. However, the going concern doubt poses job security risks.
• **Customers**: Benefit from advanced microscopy solutions, complimentary AI software, turn-key solutions, and reliable after-sales support. However, potential supply chain interruptions and quality control issues could impact service delivery.
• **Suppliers**: The company's high customer concentration and reliance on a few key suppliers (96-100% of total cost of goods sold from top 5 suppliers) could create dependency. Efficient accounts payable management (17 days turnover) is positive for suppliers.
• **Creditors**: Face risk due to the company's 'going concern' doubt and negative cash flow from operations. The loan to PT Neura Integrasi Solusi also represents a significant credit risk for the company, which indirectly impacts its ability to repay its own creditors.

Next Steps

• Complete the initial public offering and list Class A Ordinary Shares on the NYSE American.
• Implement remedial measures for identified material weaknesses in internal control over financial reporting, including engaging an external consulting firm, hiring qualified accounting personnel, and implementing training programs.
• Continue to raise debt and equity financing to support ongoing activities and address going concern doubts.
• Execute regional expansion plans in Southeast Asia, Middle East, United States, and Europe through joint ventures, strategic alliances, and digital marketing.
• Continue product research and development, including improving microsphere lens working distance, developing 3D analysis solutions, fully automated zoom microscopy, and digital pathology solutions for cancer cell analysis with AI.
• Develop new AI and cloud computing capabilities for image processing, recognition, and anomaly detection.
• Begin providing calibration and certification services to existing and new customers by the second quarter of 2025 to generate recurring income.
• Work actively to broaden the customer base to reduce concentration risk and stabilize product sales.
• Maintain listing of Class A Ordinary Shares on NYSE American for at least three years after the Closing Date.

Key Dates

Recommendation

The filing reveals a company in a precarious financial position, marked by a drastic 82.7% revenue decline and a 31.5% increase in net loss for the most recent six-month period. The explicit 'substantial doubt about our ability to continue as a going concern' is a critical red flag, indicating severe liquidity issues and an unsustainable operational model without significant external capital. While the IPO aims to raise funds, the underlying business performance is deteriorating, and the high customer concentration (99.9% from top 5 customers) exacerbates revenue volatility. The loan to an early-stage, unprofitable third party (PT Neura) adds further financial risk. Despite innovative technology and growth strategies, the immediate financial instability and the 'going concern' warning make this a highly speculative and risky investment. A seasoned investor would likely view this as a 'strong sell' given the severe financial distress and the high probability of capital loss.

Keywords

Microscopy, Super-resolution imaging, Optical microscopes, AI software, Precision measurement, Magnification, Biomedical, Semiconductors, Manufacturing, Research & Development, Singapore, Vietnam, IPO, SEC filing, F-1/A, NYSE American, Dual-class shares, Controlled company, Foreign private issuer, Going concern, Patented technology